tiprankstipranks
Trending News
More News >
Structure Therapeutics, Inc. Sponsored ADR (GPCR)
NASDAQ:GPCR
US Market

Structure Therapeutics, Inc. Sponsored ADR (GPCR) Stock Statistics & Valuation Metrics

Compare
979 Followers

Total Valuation

Structure Therapeutics, Inc. Sponsored ADR has a market cap or net worth of $910.86M. The enterprise value is $1.60B.
Market Cap$910.86M
Enterprise Value$1.60B

Share Statistics

Structure Therapeutics, Inc. Sponsored ADR has 57.34M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding57.34M
Owned by Insiders10.34%
Owned by Instutions<0.01%

Financial Efficiency

Structure Therapeutics, Inc. Sponsored ADR’s return on equity (ROE) is -0.14 and return on invested capital (ROIC) is -18.25%.
Return on Equity (ROE)-14.17%
Return on Assets (ROA)-13.56%
Return on Invested Capital (ROIC)-18.25%
Return on Capital Employed (ROCE)-18.24%
Revenue Per Employee$0
Profits Per Employee-$751,693.252
Employee Count163
Asset Turnover0.00
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Structure Therapeutics, Inc. Sponsored ADR is -43.01. Structure Therapeutics, Inc. Sponsored ADR’s PEG ratio is -8.60.
PE Ratio-43.01
PS Ratio0.00
PB Ratio6.09
Price to Fair Value6.09
Price to FCF-44.68
Price to Operating Cash Flow-45.18
PEG Ratio-8.60

Income Statement

In the last 12 months, Structure Therapeutics, Inc. Sponsored ADR had revenue of $0.00 and earned -$122.53M in profits. Earnings per share was -$0.21.
Revenue$0.00
Gross Profit-$890.66K
Operating Income-$158.23M
Pretax Income-$122.22M
Net Income-$122.53M
EBITDA-157.24M
Earnings Per Share (EPS)-0.21

Cash Flow

In the last 12 months, operating cash flow was -$116.58M and capital expenditures -$1.29M, giving a free cash flow of -$117.87M billion.
Operating Cash Flow-$116.58M
Free Cash Flow-$117.87M
Free Cash Flow per Share-$2.06

Dividends & Yields

Structure Therapeutics, Inc. Sponsored ADR pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-0.75%
Earnings Yield-2.33%

Stock Price Statistics

Beta1.59
52-Week Price Change-49.67%
50-Day Moving Average21.45
200-Day Moving Average32.26
Relative Strength Index (RSI)51.34
Average Volume (3m)870.43K

Important Dates

Structure Therapeutics, Inc. Sponsored ADR upcoming earnings date is May 8, 2025, After Close.
Last Earnings DateFeb 27, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date

Financial Position

Structure Therapeutics, Inc. Sponsored ADR as a current ratio of 24.74, with Debt / Equity ratio of <0.01
Current Ratio24.74
Quick Ratio24.74
Debt to Market Cap<0.01
Net Debt to EBITDA1.05
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Structure Therapeutics, Inc. Sponsored ADR has paid $310.00K in taxes.
Income Tax$310.00K
Effective Tax Rate-0.25%

Enterprise Valuation

Structure Therapeutics, Inc. Sponsored ADR EV to EBITDA ratio is -98.86, with an EV/FCF ratio of -132.65.
EV to Sales0.00
EV to EBITDA-98.86
EV to Free Cash Flow-132.65
EV to Operating Cash Flow-134.12

Balance Sheet

Structure Therapeutics, Inc. Sponsored ADR has $883.52M in cash and marketable securities with $3.86M in debt, giving a net cash position of -$879.66M billion.
Cash & Marketable Securities$883.52M
Total Debt$3.86M
Net Cash-$879.66M
Net Cash Per Share-$15.34
Tangible Book Value Per Share$1.48

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%

Analyst Forecast

The average price target for Structure Therapeutics, Inc. Sponsored ADR is $83.88, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$83.88
Price Target Upside427.55%
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast
EPS Growth Forecast7.57%

Scores

Smart Score2
AI Score35
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis